Subgroup analyses of SVR12 by baseline disease characteristics
| Baseline characteristic | Cohort 1 Treatment-naive | Cohort 2 Ledipasvir/ sofosbuvir or sofosbuvir-experienced | Cohort 3 Interferon-experienced | ||||
| Ledipasvir/ sofosbuvir 8 weeks (n=43) | Ledipasvir/ sofosbuvir+ ribavirin 8 weeks (n=42) | Ledipasvir/ sofosbuvir 12 weeks (n=43) | Ledipasvir/ sofosbuvir+ ribavirin 12 weeks (n=42) | Ledipasvir/ sofosbuvir+ ribavirin 12 weeks (n=11) | Ledipasvir/ sofosbuvir 12 weeks (n=36) | Ledipasvir/ sofosbuvir + ribavirin 12 weeks (n=38) | |
| Cirrhosis, n (%) | |||||||
| Yes | 6/7 (86) | 6/7 (86) | 8/9 (89) | 8/8 (100) | 3/3 (100) | 10/10 (100) | 10/10 (100) |
| No | 35/36 (97) | 32/35 (91) | 34/34 (100) | 33/34 (97) | 8/8 (100) | 24/26 (92) | 28/28 (100) |
| IL28B genotype, n (%) | |||||||
| CC | 12/12 (100) | 5/5 (100) | 11/11 (100) | 8/9 (89) | 0 | 4/5 (80) | 8/8 (100) |
| Non-CC | 29/31 (94) | 33/37 (89) | 31/32 (97) | 33/33 (100) | 11/11 (100) | 30/31 (97) | 30/30 (100) |
| Baseline HCV RNA | |||||||
| <6 000 000 IU/mL, n (%) | 39/41 (95) | 38/42 (90) | 40/41 (98) | 38/38 (100) | 7/7 (100) | 32/33 (97) | 33/34 (97) |
| ≥6 000 000 IU/mL, n (%) | 2/2 (100) | 0/0 | 2/2 (100) | 3/4 (75) | 3/3 (100) | 1/2 (50) | 4/4 (100) |
| Response to prior HCV treatment, n (%) | |||||||
| Non-responder | NA | NA | NA | NA | 0 | 18/18 (100) | 21/21 (100) |
| Relapse/breakthrough | NA | NA | NA | NA | 11/11 (100) | 14/16 (88) | 17/17 (100) |
| Interferon-intolerant | NA | NA | NA | NA | 0 | 2/2 (100) | 0 |
HCV, hepatitis C virus; NA, not applicable; SVR12, sustained virological response at 12 weeks post-treatment.